Abstract
The vascular system has an important function of supplying tissues with oxygen and nutrients and clearing waste products. Therefore, the microvasculature must be sufficiently permeable to allow the free, bidirectional passage of small molecules and gases and, to a lesser extent, of plasma proteins. It is well recognized that vascular endothelial growth factor (VEGF) can increase vascular permeability, thus playing important roles in variety of disorders, including diabetic retinopathy, nephrotic syndrome, brain edema, acute respiratory distress syndrome, and sepsis-associated hypotension. However, how vascular permeability is controlled by anti-permeable factors is not fully understood. We have recently found that pigment epithelium-derived factor (PEDF), a 50kD glycoprotein, inhibits retinal, renal and brain hyperpermeability by counteracting the biological actions of VEGF. In this review, we discuss about the pathophysiological role of PEDF in vascular permeability, especially focusing on retinal- renal disorders.
Keywords: Diabetic retinopathy, hyperpermeability, nephrotic syndrome, PEDF, VEGF
Current Molecular Medicine
Title: Anti-Vasopermeability Effects of PEDF in Retinal-Renal Disorders
Volume: 10 Issue: 3
Author(s): S. Ueda, S.-I. Yamagishi and S. Okuda
Affiliation:
Keywords: Diabetic retinopathy, hyperpermeability, nephrotic syndrome, PEDF, VEGF
Abstract: The vascular system has an important function of supplying tissues with oxygen and nutrients and clearing waste products. Therefore, the microvasculature must be sufficiently permeable to allow the free, bidirectional passage of small molecules and gases and, to a lesser extent, of plasma proteins. It is well recognized that vascular endothelial growth factor (VEGF) can increase vascular permeability, thus playing important roles in variety of disorders, including diabetic retinopathy, nephrotic syndrome, brain edema, acute respiratory distress syndrome, and sepsis-associated hypotension. However, how vascular permeability is controlled by anti-permeable factors is not fully understood. We have recently found that pigment epithelium-derived factor (PEDF), a 50kD glycoprotein, inhibits retinal, renal and brain hyperpermeability by counteracting the biological actions of VEGF. In this review, we discuss about the pathophysiological role of PEDF in vascular permeability, especially focusing on retinal- renal disorders.
Export Options
About this article
Cite this article as:
Ueda S., Yamagishi S.-I. and Okuda S., Anti-Vasopermeability Effects of PEDF in Retinal-Renal Disorders, Current Molecular Medicine 2010; 10 (3) . https://dx.doi.org/10.2174/156652410791065291
DOI https://dx.doi.org/10.2174/156652410791065291 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dendrimers and Dendritic Polymers as Anti-infective Agents: New Antimicrobial Strategies for Therapeutic Drugs
Anti-Infective Agents in Medicinal Chemistry Midazolam Plus Haloperidol as Adjuvant Analgesics to Morphine in Opium Dependent Patients: A Randomized Clinical Trial
Current Drug Abuse Reviews Adrenomedullin in Hypertension
Current Hypertension Reviews HIF Prolyl-4-hydroxylase Interacting Proteins: Consequences for Drug Targeting
Current Pharmaceutical Design Medical Management of Parkinsons Disease: Focus on Neuroprotection
Current Neuropharmacology IL-1 Cytokines in Cardiovascular Disease: Diagnostic, Prognostic and Therapeutic Implications
Cardiovascular & Hematological Agents in Medicinal Chemistry Iron Chelators in Medicinal Applications - Chemical Equilibrium Considerations in Pharmaceutical Activity
Current Medicinal Chemistry New Challenges for ACE-Inhibitors in Vascular Diseases
Drug Design Reviews - Online (Discontinued) Biochemical Markers for Brain Injury Monitoring in Children with or without Congenital Heart Diseases
CNS & Neurological Disorders - Drug Targets Targeting Kinin Receptors for the Treatment of Neurological Diseases
Current Pharmaceutical Design Inflammatory and Vascular Alterations in Sepsis: The Role of Nitric Oxide- Dependent Mechanisms
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Class IV Antiarrhythmic Agents: New Compounds Using an Old Strategy
Current Pharmaceutical Design Advanced Drug Delivery of N-Acetylcarnosine (N-Acetyl-beta-alanyl-Lhistidine), Carcinine (Beta-alanylhistamine) and L-carnosine (Beta-alanyl- L-histidine) in Targeting Peptide Compounds as Pharmacological Chaperones for Use in Tissue Engineering, Human Disease Management and Therapy: From in vitro to the Clinic
Recent Patents on Drug Delivery & Formulation The Role of Sympathetic Nervous System in the Progression of Chronic Kidney Disease in the Era of Catheter Based Sympathetic Renal Denervation
Current Clinical Pharmacology Usefulness of Home Blood Pressure in the Diagnosis and Control of Hypertension in Primary Care
Current Hypertension Reviews Toll-Like Receptors: Link between “Danger” Ligands and Plaque Instability
Current Drug Targets The Metabolic Approach in Patients with Heart Failure: Effects on Left Ventricle Remodeling
Current Pharmaceutical Design Effects of <I>Gentiana lutea</I> Root on Vascular Diseases
Current Vascular Pharmacology Hydrogen Sulfide-Based Therapies: Focus on H2S Releasing NSAIDs
Inflammation & Allergy - Drug Targets (Discontinued) Exploitation of Some Natural Products for the Prevention and/or Nutritional Treatment of SARS-CoV2 Infection
Endocrine, Metabolic & Immune Disorders - Drug Targets